News from EAS 2024: ODYSSEY program - alirocumab

PCSK9 inhibitor in ASCVD patients without acute ischemic event

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Exciting times to address residual inflammatory risk
Exciting times to address residual inflammatory risk
EAS 2024
Exciting times to address residual inflammatory risk
- Peter Libby, MD
Anti-inflammatory therapies for CVD risk prevention
Anti-inflammatory therapies for CVD risk prevention
EAS 2024
Anti-inflammatory therapies for CVD risk prevention
- Ulrich Laufs, MD, PhD
Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
EAS 2024
Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
- Evan Stein, MD, PhD
Bempedoic acid: effective tool in the toolkit for LDL-c lowering
Bempedoic acid: effective tool in the toolkit for LDL-c lowering
EAS 2024
Bempedoic acid: effective tool in the toolkit for LDL-c lowering
- Stephen Nicholls, FRACP, FACC, FESC, FAHA